Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events

Trial Profile

Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Triflusal (Primary) ; Aspirin
  • Indications Coronary artery disease; Myocardial infarction; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASTERIAS
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Feb 2017 to 31 Aug 2017.
    • 30 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top